Invention Grant
- Patent Title: Composition and method for treating a drug-resistant cancer
-
Application No.: US17828983Application Date: 2022-05-31
-
Publication No.: US11980594B2Publication Date: 2024-05-14
- Inventor: Chung-Yang Huang , Chia-Chung Hou
- Applicant: NOVELWISE PHARMACEUTICAL CORPORATION
- Applicant Address: TW Taipei
- Assignee: NOVELWISE PHARMACEUTICAL CORPORATION
- Current Assignee: NOVELWISE PHARMACEUTICAL CORPORATION
- Current Assignee Address: TW Taipei
- Agency: Birch, Stewart, Kolasch & Birch, LLP
- Main IPC: A61K31/085
- IPC: A61K31/085 ; A61K31/495 ; A61P35/00
Abstract:
The present invention provides a combination and method for treating a Temozolomide (TMZ)-resistant cancer patient, which comprises a combination of TMZ and an isoform-selective HDAC8 inhibitor, such as BMX at an effective relative ratio to overcome TMZ resistance by enhancing TMZ-mediated cytotoxic effect by downregulating the β-catenin/c-Myc/SOX2 signaling pathway and upregulating WT-p53 mediated MGMT inhibition.
Public/Granted literature
- US20230038230A1 COMPOSITION AND METHOD FOR TREATING A DRUG-RESISTANT CANCER Public/Granted day:2023-02-09
Information query
